Sanofi-aventis is pleased to announce that all of its European generic pharmaceuticals businesses will now operate under the unified brand name Zentiva. The re-branding of its generic operations in Western Europe signals sanofi-aventis’ intention to create a dynamic, growing business providing access to modern, high quality affordable medicines to 800 million people across the whole of Europe, Russia and Turkey.
By unifying the Group’s generic activities under the Zentiva brand sanofi-aventis has created the third largest generics company in the European market and more importantly the fastest growing. “ Generics are an increasingly important part of sanofi-aventis’ plans to become a diversified global healthcare company focused on patients needs commented Belen Garijo, Senior Vice-president, Global Operations, Head of Region Europe for sanofi-aventis.
The Zentiva brand was chosen by sanofi-aventis based on its success in the generics industry in Central and Eastern Europe and its clear association with modern high quality generic medicines. Zentiva also has a very positive reputation in terms of providing a high level of support and service to its key customers, an important success factor in the generics business.
By adopting a single brand the Group’s European generics business, Zentiva will be able to present a consistent and high quality image across all of its target markets. As a result, the business has become more visible and attractive to customers, business partners and to potential employees.
The new Zentiva business will supply a growing range of generic medicines to the primary care and hospital markets across Europe. Zentiva’s large, attractive and constantly expanding product portfolio includes over 350 medicines in important therapeutic areas such as cardiovascular, gastro-intestinal, urology, female health, anti-infectives, pain and CNS. Over the next several years Zentiva will be able to capitalise on its scale to invest in introducing a range of new and improved generic medicines designed to meet the evolving needs of patients.
Zentiva is led by an experienced senior management team, headed by the president of Zentiva, Rob Koremans, and supported by strong local management in each market, who have together shown the flexibility to succeed in the fast moving generics market.
Rob Koremans, President of Zentiva commented, “Sanofi-aventis has signaled its commitment to the Group’s European Generics Business by re-branding it under the name Zentiva. With its pan-European reach and scale Zentiva is ideally positioned to meet the ever changing demands of patients and payers across the region, for better and more cost effective medicines. We intend to build upon Zentiva’s leading market position in European generics based on our growing product line-up, our talented people and our focus on patients needs.”
Sanofi-aventis, a leading global pharmaceutical company, discovers, develops and distributes therapeutic solutions to improve the lives of everyone. Sanofi-aventis is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY). For more information, please visit www.sanofi-aventis.com.
About Zentiva N.V.
Zentiva, part of the sanofi-aventis Group, is a leading provider of modern, high quality affordable medicines in Central and Eastern Europe. Zentiva is headquartered in Prague, Czech Republic.
Contacts for more information
Carol Levasseur-Brockway, Communications Director
Tel: +420 267 24 35 18
Bernard Peyrical, Associate VP Communication, Europe
Tel: + 33 1 57 63 22 36